Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
Saved in:
| Title: | Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial. |
|---|---|
| Authors: | Ferrante, Marc1 (AUTHOR) marc.ferrante@uzleuven.be, Irving, Peter M2 (AUTHOR), Abreu, Maria T3 (AUTHOR), Axler, Jeffrey4 (AUTHOR), Gao, Xiang5 (AUTHOR), Cao, Qian6 (AUTHOR), Fujii, Toshimitsu7 (AUTHOR), Rausch, Astrid8 (AUTHOR), Torres, Joana9,10,11 (AUTHOR), Neimark, Ezequiel12 (AUTHOR), Song, Alexandra12 (AUTHOR), Wallace, Kori12 (AUTHOR), Kligys, Kristina12 (AUTHOR), Berg, Sofie12 (AUTHOR), Liao, Xiaomei12 (AUTHOR), Zhou, Qing12 (AUTHOR), Kalabic, Jasmina13 (AUTHOR), Feagan, Brian14 (AUTHOR), Panaccione, Remo15 (AUTHOR) |
| Source: | Journal of Crohn's & Colitis. Mar2024, Vol. 18 Issue 3, p416-423. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
